ATLANTA, October 25, 2019 – Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that it has entered into a $20.0 million common stock purchase agreement with Lincoln Park Capital Fund, LLC (“LPC”), a Chicago-based institutional investor.
Upon entering into the agreement, LPC purchased $1.0 million of Alimera’s registered common stock at $0.50 per share, which represents a 35% premium to the closing market price of the stock on October 24, 2019.
Thereafter and upon satisfaction of the conditions in the agreement, Alimera, from time to time over a 36-month period, will have the right, in its sole discretion, to sell up to an additional $19.0 million of its common stock to LPC. Alimera will control the timing and amount of any future sale of shares of common stock to LPC, and LPC is obligated to make purchases according to Alimera’s direction, as governed by the agreement. There are no upper limits to the price per share LPC may pay to purchase common stock from Alimera, and the purchase price of the shares will be based on the prevailing market prices of Alimera’s common shares at the time of each sale to LPC.
“The LPC commitment affords Alimera a flexible option to invest in our current business to pursue strategies to leverage our global sales infrastructure and build a leading company focused on the treatment of retinal diseases,” said Rick Eiswirth, president and CEO of Alimera. “The terms of the Agreement provide a low-cost option with no restrictive covenants or warrants. In addition, we have gained an institutional investor that has made a commitment in support of our company, as evidenced by their initial investment at a premium to the market, as we make progress in the business and build shareholder value.”
Alimera will use the net proceeds from the sales for general corporate purposes, including funding intended to facilitate the continued commercialization and growth of ILUVIEN® in the United States and in international territories, launches of ILUVIEN in new international territories, launches of ILUVIEN’s second indication for non-infectious posterior uveitis in international markets, and for potential strategic initiatives.
LPC has agreed not to engage in any direct or indirect short selling or hedging of Alimera’s shares of common stock. There are no limitations on the use of proceeds, and there are no rights of first refusal, participation rights, penalties or liquidated damages in the purchase agreement. As consideration for Lincoln Park’s commitment to purchase shares of common stock pursuant to the purchase agreement, Alimera issued 1,363,636 shares of common stock to Lincoln Park. Alimera may terminate the purchase agreement at any time, at its discretion, without any additional cost or penalty. The common stock purchase agreement and a related registration rights agreement are summarized in Alimera’s Current Report on Form 8-K filed today with the Securities and Exchange Commission (SEC).
Successful Trading is the art of minimizing long term risk and maximizing capital allocation.
Recent ALIM News
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 05/16/2024 09:06:29 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 09:04:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 12:46:39 PM
- Alimera Sciences Reports First Quarter 2024 Results • GlobeNewswire Inc. • 05/14/2024 11:30:00 AM
- Alimera Announces Scientific Data Highlighting YUTIQ® to be Presented at Upcoming Association for Research in Vision and Ophthalmology and Retina World Congress Conferences • GlobeNewswire Inc. • 05/07/2024 12:00:00 PM
- Alimera Sciences to Report First Quarter 2024 Financial Results on May 14, 2024, and Provide Corporate Update • GlobeNewswire Inc. • 04/30/2024 12:00:00 PM
- Alimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 03/20/2024 12:00:00 PM
- Alimera Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRCR Retina Network • GlobeNewswire Inc. • 03/19/2024 12:00:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/08/2024 10:23:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 01:32:14 PM
- Alimera Sciences Reports Fourth Quarter and Full Year 2023 Results • GlobeNewswire Inc. • 03/07/2024 12:30:00 PM
- Alimera Sciences to Report Fourth Quarter and Full Year 2023 Financial Results on March 7, 2024, and Provide Corporate Update • GlobeNewswire Inc. • 02/29/2024 01:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 09:43:35 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 09:24:52 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 08:27:46 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/09/2024 10:25:06 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/09/2024 10:14:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2024 10:08:13 PM
- The UK National Institute for Health and Care Excellence (NICE) Issues Final Draft Guidance to Provide Patients with a Natural Lens (Phakic Eye) Being Treated for Chronic Diabetic Macular Edema Access to ILUVIEN® • GlobeNewswire Inc. • 02/08/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/11/2024 05:49:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 09:02:52 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 09:02:04 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/04/2024 09:01:17 PM
- Alimera Completes Recruitment for the Synchronicity Study • GlobeNewswire Inc. • 01/04/2024 01:00:00 PM
- Alimera Sciences Names Elliot Maltz as Chief Financial Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 01/02/2024 01:00:00 PM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM
Avant Technologies to Revolutionize Data Center Management with Proprietary AI Software Platform • AVAI • May 16, 2024 8:00 AM